DEADLINES for 2015 RFPs:
**Letter of intent is due at least two weeks prior to each deadline for consideration in that funding cycle (except for the CAPA Consortium - see below)
CAPA CONSORTIUM RFP: The ADDF created the Cohorts for Alzheimer’s Prevention Action (CAPA) Consortium to strengthen the evidence for potential preventative treatments. This program will fund specific analyses across a minimum of 5 longitudinal cohorts to examine the association of actionable interventions with the risk of cognitive aging, Alzheimer’s disease, related dementias, or biomarkers related to brain aging and neurodegeneration. Letters of intent will be accepted until the full application due date. The full application (with a letter-of-support from each cohort participating in the proposal) is due on March 5, 2015. See full RFP here. See spreadsheet of CAPA Consortium cohorts here.
PRECLINICAL DRUG DISCOVERY RFP: The Alzheimer's Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive againg. See full RFP here.
PACT RFP: The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. See full RFP here.
ADDF/NIH RFP: The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling. See full RFP.